A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations

NCT05157776 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

72

Enrollment

OTHER

Sponsor class

Conditions

NSCLC, Stage IIIA
EGF-R Negative Non-Small Cell Lung Cancer
ALK Negative NSCLC

Interventions

DRUG: PD-1 and chemotherapy

Sponsor

Tongji University